Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men
Background. There is an international epidemic of hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)–infected men who have sex with men. Sustained virologic response (SVR) rates with pegylated interferon and ribavirin treatment are higher in these men during acute HCV than du...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2014-03, Vol.58 (6), p.873-879 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 879 |
|---|---|
| container_issue | 6 |
| container_start_page | 873 |
| container_title | Clinical infectious diseases |
| container_volume | 58 |
| creator | Fierer, Daniel S. Dieterich, Douglas T. Mullen, Michael P. Branch, Andrea D. Uriel, Alison J. Carriero, Damaris C. van Seggelen, Wouter O. Hijdra, Rosanne M. Cassagnol, David G. |
| description | Background. There is an international epidemic of hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)–infected men who have sex with men. Sustained virologic response (SVR) rates with pegylated interferon and ribavirin treatment are higher in these men during acute HCV than during chronic HCV, but treatment is still lengthy and SVR rates are suboptimal. Methods. We performed a pilot study of combination therapy with telaprevir, pegylated interferon, and ribavirin in acute genotype 1 HCV infection in HIV-infected men. Men who were treated prior to the availability of, or ineligible for, telaprevir were the comparator group. The primary endpoint was SVR12, defined as an HCV viral load |
| doi_str_mv | 10.1093/cid/cit799 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3935497</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>24031725</jstor_id><sourcerecordid>24031725</sourcerecordid><originalsourceid>FETCH-LOGICAL-c491t-33837f1acdd6e199509ff610849f11fc3195d79fae12eefcf706d15b02cd26b93</originalsourceid><addsrcrecordid>eNqN0UFrFDEUB_BBFFurF-9KQAQpjOZNJjPJRSiLugstXtZeQzbzYrPMJmuSKfjtzTJrbT31EBKSX_685FXVa6AfgUr2ybihjNxL-aQ6Bc76uuMSnpY15aJuBRMn1YuUtpQCCMqfVydNy1gnoT2t1msc9T7irYvEeZJvkKwj6rxDn0mw5MJMGckS9zq77BJZkGsXp0RW3qLJLvjDreXqup43cCBX6F9Wz6weE746zmfVj69f1otlffn922pxcVmbVkKuGROst6DNMHQIUnIqre2AilZaAGsYSD700mqEBtEa29NuAL6hjRmabiPZWfV5zt1Pmx0OptQc9aj20e10_K2CdurhiXc36me4VUwy3sq-BHw4BsTwa8KU1c4lg-OoPYYpKeCFtV0j6CMoLZm0402h7_6j2zBFX37ioDhrABgUdT4rE0NKEe1d3UDVoa-q9FXNfS347f2X3tG_jSzg_RHoZPRoo_bGpX9OMBBtw4p7M7ttyiHey6EM-oazP58MtFk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1505321131</pqid></control><display><type>article</type><title>Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Fierer, Daniel S. ; Dieterich, Douglas T. ; Mullen, Michael P. ; Branch, Andrea D. ; Uriel, Alison J. ; Carriero, Damaris C. ; van Seggelen, Wouter O. ; Hijdra, Rosanne M. ; Cassagnol, David G.</creator><creatorcontrib>Fierer, Daniel S. ; Dieterich, Douglas T. ; Mullen, Michael P. ; Branch, Andrea D. ; Uriel, Alison J. ; Carriero, Damaris C. ; van Seggelen, Wouter O. ; Hijdra, Rosanne M. ; Cassagnol, David G. ; New York Acute Hepatitis C Surveillance Networka ; New York Acute Hepatitis C Surveillance Network ; for the New York Acute Hepatitis C Surveillance Network</creatorcontrib><description>Background. There is an international epidemic of hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)–infected men who have sex with men. Sustained virologic response (SVR) rates with pegylated interferon and ribavirin treatment are higher in these men during acute HCV than during chronic HCV, but treatment is still lengthy and SVR rates are suboptimal. Methods. We performed a pilot study of combination therapy with telaprevir, pegylated interferon, and ribavirin in acute genotype 1 HCV infection in HIV-infected men. Men who were treated prior to the availability of, or ineligible for, telaprevir were the comparator group. The primary endpoint was SVR12, defined as an HCV viral load <5 IU/mL at least 12 weeks after completing treatment. Results. In the telaprevir group, 84% (16/19) of men achieved SVR12 vs 63% (30/48) in the comparator group. Among men with SVR, median time to undetectable viral load was week 2 in the telaprevir group vs week 4 in the comparator group, and 94% vs 53% had undetectable viral loads at week 4. Most patients (81%) who achieved SVR in the telaprevir group received ≤12 weeks of treatment and there were no relapses after treatment. The overall safety profile was similar to that known for telaprevir-based regimens. Conclusions. Incorporating telaprevir into treatment of acute genotype 1 HCV in HIV-infected men halved the treatment duration and increased the SVR rate. Larger studies should be done to confirm these findings. Clinicians should be alert to detect acute HCV infection of HIV-infected men to take advantage of this effective therapy and decrease further transmission in this epidemic.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/cit799</identifier><identifier>PMID: 24336914</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Oxford: OXFORD UNIVERSITY PRESS</publisher><subject>Adult ; AIDS ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral drugs ; Antiviral agents ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Comparators ; Drug Therapy, Combination ; Epidemics ; Genotypes ; Hepacivirus ; Hepatitis ; Hepatitis C ; Hepatitis C - drug therapy ; Hepatitis C - virology ; HIV ; HIV infections ; HIV Infections - virology ; HIV/AIDS ; Homosexuality, Male ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infections ; Infectious diseases ; Interferon ; Interferons ; Male ; Medical sciences ; Medical treatment ; Middle Aged ; Oligopeptides - therapeutic use ; Pharmacology. Drug treatments ; Pilot Projects ; Polymerase chain reaction ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral hepatitis ; Virology</subject><ispartof>Clinical infectious diseases, 2014-03, Vol.58 (6), p.873-879</ispartof><rights>Copyright © 2014 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Oxford University Press, UK Mar 15, 2014</rights><rights>The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: . 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c491t-33837f1acdd6e199509ff610849f11fc3195d79fae12eefcf706d15b02cd26b93</citedby><cites>FETCH-LOGICAL-c491t-33837f1acdd6e199509ff610849f11fc3195d79fae12eefcf706d15b02cd26b93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/24031725$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/24031725$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,777,781,800,882,27905,27906,57998,58231</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28318423$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24336914$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fierer, Daniel S.</creatorcontrib><creatorcontrib>Dieterich, Douglas T.</creatorcontrib><creatorcontrib>Mullen, Michael P.</creatorcontrib><creatorcontrib>Branch, Andrea D.</creatorcontrib><creatorcontrib>Uriel, Alison J.</creatorcontrib><creatorcontrib>Carriero, Damaris C.</creatorcontrib><creatorcontrib>van Seggelen, Wouter O.</creatorcontrib><creatorcontrib>Hijdra, Rosanne M.</creatorcontrib><creatorcontrib>Cassagnol, David G.</creatorcontrib><creatorcontrib>New York Acute Hepatitis C Surveillance Networka</creatorcontrib><creatorcontrib>New York Acute Hepatitis C Surveillance Network</creatorcontrib><creatorcontrib>for the New York Acute Hepatitis C Surveillance Network</creatorcontrib><title>Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Background. There is an international epidemic of hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)–infected men who have sex with men. Sustained virologic response (SVR) rates with pegylated interferon and ribavirin treatment are higher in these men during acute HCV than during chronic HCV, but treatment is still lengthy and SVR rates are suboptimal. Methods. We performed a pilot study of combination therapy with telaprevir, pegylated interferon, and ribavirin in acute genotype 1 HCV infection in HIV-infected men. Men who were treated prior to the availability of, or ineligible for, telaprevir were the comparator group. The primary endpoint was SVR12, defined as an HCV viral load <5 IU/mL at least 12 weeks after completing treatment. Results. In the telaprevir group, 84% (16/19) of men achieved SVR12 vs 63% (30/48) in the comparator group. Among men with SVR, median time to undetectable viral load was week 2 in the telaprevir group vs week 4 in the comparator group, and 94% vs 53% had undetectable viral loads at week 4. Most patients (81%) who achieved SVR in the telaprevir group received ≤12 weeks of treatment and there were no relapses after treatment. The overall safety profile was similar to that known for telaprevir-based regimens. Conclusions. Incorporating telaprevir into treatment of acute genotype 1 HCV in HIV-infected men halved the treatment duration and increased the SVR rate. Larger studies should be done to confirm these findings. Clinicians should be alert to detect acute HCV infection of HIV-infected men to take advantage of this effective therapy and decrease further transmission in this epidemic.</description><subject>Adult</subject><subject>AIDS</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral drugs</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Comparators</subject><subject>Drug Therapy, Combination</subject><subject>Epidemics</subject><subject>Genotypes</subject><subject>Hepacivirus</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - virology</subject><subject>HIV</subject><subject>HIV infections</subject><subject>HIV Infections - virology</subject><subject>HIV/AIDS</subject><subject>Homosexuality, Male</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Interferon</subject><subject>Interferons</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Oligopeptides - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Polymerase chain reaction</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral hepatitis</subject><subject>Virology</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0UFrFDEUB_BBFFurF-9KQAQpjOZNJjPJRSiLugstXtZeQzbzYrPMJmuSKfjtzTJrbT31EBKSX_685FXVa6AfgUr2ybihjNxL-aQ6Bc76uuMSnpY15aJuBRMn1YuUtpQCCMqfVydNy1gnoT2t1msc9T7irYvEeZJvkKwj6rxDn0mw5MJMGckS9zq77BJZkGsXp0RW3qLJLvjDreXqup43cCBX6F9Wz6weE746zmfVj69f1otlffn922pxcVmbVkKuGROst6DNMHQIUnIqre2AilZaAGsYSD700mqEBtEa29NuAL6hjRmabiPZWfV5zt1Pmx0OptQc9aj20e10_K2CdurhiXc36me4VUwy3sq-BHw4BsTwa8KU1c4lg-OoPYYpKeCFtV0j6CMoLZm0402h7_6j2zBFX37ioDhrABgUdT4rE0NKEe1d3UDVoa-q9FXNfS347f2X3tG_jSzg_RHoZPRoo_bGpX9OMBBtw4p7M7ttyiHey6EM-oazP58MtFk</recordid><startdate>20140315</startdate><enddate>20140315</enddate><creator>Fierer, Daniel S.</creator><creator>Dieterich, Douglas T.</creator><creator>Mullen, Michael P.</creator><creator>Branch, Andrea D.</creator><creator>Uriel, Alison J.</creator><creator>Carriero, Damaris C.</creator><creator>van Seggelen, Wouter O.</creator><creator>Hijdra, Rosanne M.</creator><creator>Cassagnol, David G.</creator><general>OXFORD UNIVERSITY PRESS</general><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>7U2</scope><scope>5PM</scope></search><sort><creationdate>20140315</creationdate><title>Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men</title><author>Fierer, Daniel S. ; Dieterich, Douglas T. ; Mullen, Michael P. ; Branch, Andrea D. ; Uriel, Alison J. ; Carriero, Damaris C. ; van Seggelen, Wouter O. ; Hijdra, Rosanne M. ; Cassagnol, David G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c491t-33837f1acdd6e199509ff610849f11fc3195d79fae12eefcf706d15b02cd26b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>AIDS</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral drugs</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Comparators</topic><topic>Drug Therapy, Combination</topic><topic>Epidemics</topic><topic>Genotypes</topic><topic>Hepacivirus</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - virology</topic><topic>HIV</topic><topic>HIV infections</topic><topic>HIV Infections - virology</topic><topic>HIV/AIDS</topic><topic>Homosexuality, Male</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Interferon</topic><topic>Interferons</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Oligopeptides - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Polymerase chain reaction</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral hepatitis</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fierer, Daniel S.</creatorcontrib><creatorcontrib>Dieterich, Douglas T.</creatorcontrib><creatorcontrib>Mullen, Michael P.</creatorcontrib><creatorcontrib>Branch, Andrea D.</creatorcontrib><creatorcontrib>Uriel, Alison J.</creatorcontrib><creatorcontrib>Carriero, Damaris C.</creatorcontrib><creatorcontrib>van Seggelen, Wouter O.</creatorcontrib><creatorcontrib>Hijdra, Rosanne M.</creatorcontrib><creatorcontrib>Cassagnol, David G.</creatorcontrib><creatorcontrib>New York Acute Hepatitis C Surveillance Networka</creatorcontrib><creatorcontrib>New York Acute Hepatitis C Surveillance Network</creatorcontrib><creatorcontrib>for the New York Acute Hepatitis C Surveillance Network</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fierer, Daniel S.</au><au>Dieterich, Douglas T.</au><au>Mullen, Michael P.</au><au>Branch, Andrea D.</au><au>Uriel, Alison J.</au><au>Carriero, Damaris C.</au><au>van Seggelen, Wouter O.</au><au>Hijdra, Rosanne M.</au><au>Cassagnol, David G.</au><aucorp>New York Acute Hepatitis C Surveillance Networka</aucorp><aucorp>New York Acute Hepatitis C Surveillance Network</aucorp><aucorp>for the New York Acute Hepatitis C Surveillance Network</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2014-03-15</date><risdate>2014</risdate><volume>58</volume><issue>6</issue><spage>873</spage><epage>879</epage><pages>873-879</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>Background. There is an international epidemic of hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)–infected men who have sex with men. Sustained virologic response (SVR) rates with pegylated interferon and ribavirin treatment are higher in these men during acute HCV than during chronic HCV, but treatment is still lengthy and SVR rates are suboptimal. Methods. We performed a pilot study of combination therapy with telaprevir, pegylated interferon, and ribavirin in acute genotype 1 HCV infection in HIV-infected men. Men who were treated prior to the availability of, or ineligible for, telaprevir were the comparator group. The primary endpoint was SVR12, defined as an HCV viral load <5 IU/mL at least 12 weeks after completing treatment. Results. In the telaprevir group, 84% (16/19) of men achieved SVR12 vs 63% (30/48) in the comparator group. Among men with SVR, median time to undetectable viral load was week 2 in the telaprevir group vs week 4 in the comparator group, and 94% vs 53% had undetectable viral loads at week 4. Most patients (81%) who achieved SVR in the telaprevir group received ≤12 weeks of treatment and there were no relapses after treatment. The overall safety profile was similar to that known for telaprevir-based regimens. Conclusions. Incorporating telaprevir into treatment of acute genotype 1 HCV in HIV-infected men halved the treatment duration and increased the SVR rate. Larger studies should be done to confirm these findings. Clinicians should be alert to detect acute HCV infection of HIV-infected men to take advantage of this effective therapy and decrease further transmission in this epidemic.</abstract><cop>Oxford</cop><pub>OXFORD UNIVERSITY PRESS</pub><pmid>24336914</pmid><doi>10.1093/cid/cit799</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2014-03, Vol.58 (6), p.873-879 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3935497 |
| source | MEDLINE; Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult AIDS Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral drugs Antiviral agents Antiviral Agents - therapeutic use Biological and medical sciences Comparators Drug Therapy, Combination Epidemics Genotypes Hepacivirus Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatitis C - virology HIV HIV infections HIV Infections - virology HIV/AIDS Homosexuality, Male Human immunodeficiency virus Human viral diseases Humans Infections Infectious diseases Interferon Interferons Male Medical sciences Medical treatment Middle Aged Oligopeptides - therapeutic use Pharmacology. Drug treatments Pilot Projects Polymerase chain reaction Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral hepatitis Virology |
| title | Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T01%3A43%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Telaprevir%20in%20the%20Treatment%20of%20Acute%20Hepatitis%20C%20Virus%20Infection%20in%20HIV-Infected%20Men&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Fierer,%20Daniel%20S.&rft.aucorp=New%20York%20Acute%20Hepatitis%20C%20Surveillance%20Networka&rft.date=2014-03-15&rft.volume=58&rft.issue=6&rft.spage=873&rft.epage=879&rft.pages=873-879&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1093/cid/cit799&rft_dat=%3Cjstor_pubme%3E24031725%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1505321131&rft_id=info:pmid/24336914&rft_jstor_id=24031725&rfr_iscdi=true |